Sandoz Inc. recalled 263 vials of Cyclophosphamide Injection on September 5, 2025. The recall follows cGMP deviations related to temperature excursions during transportation. Healthcare providers and consumers must stop using the product immediately.
cGMP deviations: Temperature excursion during transportation.
Consumers and healthcare providers should stop using this product immediately. Contact Sandoz Inc or your healthcare provider for guidance. Notification method: Letter
The recalled product is Cyclophosphamide Injection 500 mg/5 mL, Lot # 110459, with an expiration date of February 28, 2027. It is manufactured in Austria by Fareva Unterach GmbH. The product is distributed nationwide in the USA.
The recall is due to cGMP deviations, specifically temperature excursions that could compromise product integrity. These issues pose a significant risk to patient safety.
No specific incidents or injuries have been reported related to this recall. The recall is precautionary based on manufacturing deviations.
Stop using the recalled product immediately. Contact Sandoz Inc. or your healthcare provider for further guidance.
For more information, contact Sandoz Inc. at their official website or through the recall notification letter.
Glenmark Pharmaceuticals Inc. recalled 13,824 tubes of Azelaic Acid Gel on September 17, 2025. The recall stems from market complaints regarding a gritty texture. Consumers should stop using the product immediately and contact their healthcare provider.
Skin MD by Dr Monika Kiripolsky recalled its Body Acne Cleanser on September 12, 2025. The recall follows the discovery of elevated benzene levels in the product. This contamination poses a high health risk to consumers in California and Georgia.
Private Label Skin Care recalled its Micronized BPO Gel Cleanser 10% on September 12, 2025. Elevated benzene levels prompted the recall in California and Georgia. Consumers must stop using the product immediately and seek guidance from healthcare providers.